CMOs earn €8.4m in EU grants to help scale-up manufacturing of thermo-stable vaccines

By Zachary Brennan

- Last updated on GMT

The EU Horizon 2020 project, which will last for three-and-a-half years, is named MACIVIVA, which stands for “Manufacturing process for Cold-chain Independent Virosome-based Vaccines.”
The EU Horizon 2020 project, which will last for three-and-a-half years, is named MACIVIVA, which stands for “Manufacturing process for Cold-chain Independent Virosome-based Vaccines.”

Related tags European union

A new round of €8.4m ($8.9m) in grants will help develop a scalable manufacturing process to wean vaccines off of their cold-chain dependency and help ensure they can be manufactured as stable and temperature independent.

The funds, part of which were awarded to CDMO Catalent, will fund the evaluation, development and manufacturing scale-up of thermo stable and cold-chain independent nano-pharmaceutical virosome-based vaccine candidates. 

Of the €8.4m, a total of €5.3 million is funded as part of Horizon 2020, the European Union research and innovation framework program, and up to €3.1m of the funding will be provided by the Swiss State Secretariat for Education, Research and Innovation (SERI) for the Swiss based consortium partners, which include Mymetics and Bachem. 

The EU Horizon 2020 project, which will last for three-and-a-half years, is named MACIVIVA, which stands for “Manufacturing process for Cold-chain Independent Virosome-based Vaccines​.” 

The project brings together leading contract manufacturers, including Catalent’s Swindon, UK facility, the manufacturing hub of its Zydis fast-dissolve formulation technology, as well as other companies’ expertise for spray drying, freeze drying and analytical techniques to develop a scalable manufacturing process to achieve thermos-stable and cold-chain independent virosome-based vaccines. 

With more than 90% of the existing vaccines dependent on the cold-chain and the resulting detrimental impact on availability, efficacy and costs of these vaccines in developing countries, there is an undisputable need to innovate and manufacture vaccines that are stable and temperature independent​,” said Ronald Kempers, CEO of Mymetics. 

Germany’s Chimera Biotech and the UK’s Upperton were also awarded grants. 

“Catalent is pleased to be part of this consortium of cross-industry partners bringing innovative technologies together to address a serious global issue in the over-reliance on the cold chain with existing vaccines,”​ added Barry Littlejohns, Catalent’s President of Advanced Delivery Technologies. 

Related news

Related products

show more

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Thermo Fisher Scientific - Biosciences | 01-Jan-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Create Better Biologic Treatments with Catalent

Create Better Biologic Treatments with Catalent

Catalent | 06-Dec-2022 | Product Brochure

Your biologics possess a high level of complexities and technical challenges. That’s why development is key to ensuring the successful delivery of your...

Related suppliers

Follow us

Products

View more

Webinars